SuperworthNextCure EPS NXTC
Diluted earnings per share by quarter and over the last twelve months, from 2018.
- Last 12 months, to Jun 30, 2026
- −$10.27
- Latest quarter, Q2 FY26
- −$2.80
- Fiscal year 2025
- −$21.59
NextCure's earnings per share was −$10.27 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$2.80.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$21.59 | n/a |
| FY2024 | −$23.85 | n/a |
| FY2023 | −$27.00 | n/a |
| FY2022 | −$32.28 | n/a |
| FY2021 | −$30.12 | n/a |
| FY2020 | −$16.20 | n/a |
| FY2019 | −$70.56 | n/a |
| FY2018 | −$199.68 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$2.80 | n/a | −$10.27 | |
| Q1 FY26 | −$1.87 | n/a | −$18.76 | |
| Q4 FY25 | −$2.38 | n/a | −$21.59 | |
| Q3 FY25 | −$3.22 | n/a | −$24.18 | |
| Q2 FY25 | −$11.29 | n/a | −$25.91 | |
| Q1 FY25 | −$4.70 | n/a | −$21.23 | |
| Q4 FY24 | −$4.97 | n/a | −$23.85 | |
| Q3 FY24 | −$4.95 | n/a | −$25.12 | |
| Q2 FY24 | −$6.61 | n/a | −$26.29 | |
| Q1 FY24 | −$7.32 | n/a | −$27.36 | |
| Q4 FY23 | −$6.24 | n/a | −$27.00 | |
| Q3 FY23 | −$6.12 | n/a | −$28.20 |
Against its peers
Companies in Drug Manufacturers - General nearest NextCure's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| NXTCNextCure | −$10.27 | |
| ATNMActinium Pharmaceuticals | $0.36 | |
| SPROSpero Therapeutics | $0.11 | |
| LFVNLifevantage | $0.40 | −46% a year |
| NATRNatures Sunshine Products | $1.01 | +36% a year |
| Peer median | $0.38 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on NextCure
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.